Andrés Felipe Cardona Zorrilla’s Post

"Optimizing Drug Discovery for Breast Cancer in a Laboratory Environment Using Machine Learning" research paper is published in the IEEE 2024 International Conference on Wireless Communications Signal Processing and Networking (WiSPNET). https://lnkd.in/dsYuwaUw This paper has clinical analysis of 123 patients suffering from Breast Cancer( Dataset collected from Maharastra Region).The dataset’s impedance dynamics data provide evidence for treatment efficacy. Therapeutic strategies need to be adjusted for particular patients and their stage of cancer since the results underscore the usefulness of personalized breast cancer therapy.

#ESMOBreast24: Learn how to integrate innovation into your daily practice and improve patient outcomes. Register by 📅17 April for preferential rates and see you in Berlin, Germany, or online. 🔗https://ow.ly/TqWT50QYvNh During this event, you will be able to: ➡️ Understand recent developments in novel diagnostics, biomarkers and treatments in breast cancer ➡️ Be updated on the rapid development of novel antibody drug conjugates for breast cancer ➡️ Gain insights on new strategies for Luminal, HER2 positive, HER2-low and triple negative breast cancer ➡️ Understand special considerations for different subgroups of patients with breast cancer

Si Wu from my team will present how to use RWD for drug discovery in AACR.

Innovative science is what pushes oncology clinical research forward. At the #AACR2024 conference, the #TFSTeam walked miles of posters and gained insights into the latest innovations shaping the future of cancer treatment. Swipe to see our journey in numbers and key moments captured at American Association for Cancer Research annual conference! Interested in learning how these advancements can accelerate your early phase oncology trials? Reach out to discover how TFS can help you drive better outcomes for cancer patients worldwide. Let's innovate together! #OncologyCRO #OncologyClinicalResearch

Join the poster session at the American Association for Cancer Research (AACR) Annual Meeting on April 8 from 9:00 AM to 12:30 PM for a presentation titled: "Harness the power of real-world-data for oncology target and biomarker research: A case study by applying clinic-genomics data for 2,659 lung cancer patients and beyond," presented by AbbVie. Discover how real-world data (RWD) is revolutionizing oncology research! Delve into the comprehensive analysis of 2,659 lung cancer patients, combining ConcertAI electronic health records (EHR) with Caris Life Sciences Lab data. The findings showcase the potential of RWD in identifying unique molecular signatures, analyzing patient treatment patterns, and unlocking personalized medicine. Don't miss out on this session! Learn more: https://hubs.ly/Q02qDnWG0 #AACR #RealWorldData #OncologyResearch

Meet Colin Weekes, MD, PhD, from Criterium's Academic GI Cancer Consortium and Massachusetts General Hospital. Dr. Weekes has an active clinic focus on the management of all gastrointestinal malignancies with a focus on pancreas cancer patients and early phase clinical studies as part of the developmental therapeutics clinic. He currently, directs the pancreas cancer clinical trial program. Learn more about Dr. Weekes: https://lnkd.in/eV5QusH5 #GIcancer #oncology #cancerresearch

KRAS Inhibitors is EOS Intelligence's focus for June and we will be publishing new content every week. The KRAS oncogene has long been a challenging target in cancer therapy, but recent breakthroughs are transforming the competitive landscape. As the race to develop effective KRAS inhibitors intensifies, understanding this dynamic market is crucial for stakeholders. Here's a closer look at the innovations, challenges, and key players shaping the KRAS competitive landscape. The race to develop effective KRAS inhibitors represents a pivotal moment in cancer treatment. Companies that navigate this competitive landscape successfully will unlock new potentials in oncology, bringing hope to patients and advancing the frontiers of medicine. If you wish to discuss, reach out! #KRASInhibitors #CancerTherapy #OncologyInnovation #PrecisionMedicine #PharmaLeadership

Does implantation site matter when evaluating immune response in preclinical cancer models? Find out at our Society for Immunotherapy of Cancer (SITC) poster session this Friday. Certis Senior Director of Immuno-Oncology Rajeev Shrimali, Ph.D., will discuss how subcutaneous and orthotopic patient-derived xenograft models exhibit differential immune responses and may determine therapeutic outcomes. Learn more about our clinically relevant models: https://hubs.la/Q027q9N10. #SITC23 #Immunotherapy #TumorModels #CancerModels #CancerResearch #CertaintyIsPriceless #TumorBank

Excited to present at #SITC23. Stop by our poster to learn how our clinically relevant PDX tumor models including tumor location site can aid in meaningful translation of your pre-clinical candidates to clinic with certainty. Reach out to our team Michael Boice & Rajeev Shrimali, Ph.D. at #SITC23 to discuss your preclinical immuno-oncology needs.  #immunotherapy #cartcells #bispecifics #antibodies #targetedtherapy #antibodydrugconjugates #pdxmodels #humanize #biomarkers

New Biomarker Research Enhances Prostate Cancer Treatment Explore the latest findings on the HSD3B1 biomarker and its impact on prostate cancer treatment. This research offers vital insights for more personalized and effective treatment options, marking a significant step forward in patient care. Read here: https://hubs.li/Q02cZxlg0